JP2012522788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522788A5 JP2012522788A5 JP2012503632A JP2012503632A JP2012522788A5 JP 2012522788 A5 JP2012522788 A5 JP 2012522788A5 JP 2012503632 A JP2012503632 A JP 2012503632A JP 2012503632 A JP2012503632 A JP 2012503632A JP 2012522788 A5 JP2012522788 A5 JP 2012522788A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- antibody
- antagonist
- disease
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 10
- 108090001123 antibodies Proteins 0.000 claims 10
- 102100008982 IL17A Human genes 0.000 claims 6
- 101710003110 IL17A Proteins 0.000 claims 6
- 102100015975 IL17F Human genes 0.000 claims 6
- 101700007032 IL17F Proteins 0.000 claims 6
- 230000003042 antagnostic Effects 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 206010022489 Insulin resistance Diseases 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000004218 Insulin-like growth factor I Human genes 0.000 claims 1
- 108090000723 Insulin-like growth factor I Proteins 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (17)
- インスリン抵抗性疾患を治療するための医薬の製造におけるIL−17Aおよび/またはIL−17Fアンタゴニストの使用。
- それを必要とする哺乳動物に有効量のIL−17Aおよび/またはIL−17Fアンタゴニストを投与することを含む、請求項1に記載の使用。
- 前記哺乳動物は、ヒトであり、かつ、前記投与は全身性である、請求項2に記載の使用。
- 前記疾患は、非インスリン依存性真性糖尿病(NIDDM)、肥満、卵巣アンドロゲン過剰、および高血圧から成る群から選択される、請求項1に記載の使用。
- 前記疾患は、NIDDMまたは肥満である、請求項4に記載の使用。
- 前記IL−17Aおよび/またはIL−17Fアンタゴニストは、抗体またはそのフラグメントである、請求項1から5の何れか一項に記載の使用。
- 前記抗体は、抗IL−17A、抗IL−17F、抗IL−17A/F、抗IL−17Rc、および抗IL−17RA抗体から成る群から選択される抗体である、請求項6に記載の使用。
- 前記抗体は、モノクローナル抗体である、請求項7に記載の使用。
- 前記抗体は、キメラ、ヒト化、またはヒト抗体である、請求項8に記載の使用。
- 前記抗体は、二重特異性、多特異性、または交差反応性抗体である、請求項9に記載の使用。
- 前記医薬が、有効量のインスリン抵抗性治療薬をさらに含む、請求項7に記載の使用。
- 前記インスリン抵抗性治療薬は、インスリン、IGF−1、またはスルホニル尿素である、請求項11に記載の使用。
- 前記医薬が、前記インスリン抵抗性疾患を治療することができる、有効量のさらなる薬剤をさらに含む、請求項12に記載の使用。
- 前記さらなる薬剤は、Dickkopf−5(Dkk−5)である、請求項13に記載の使用。
- 薬学的に許容される賦形剤と混合した、IL−17Aおよび/またはIL−17Fアンタゴニストを含む、インスリン抵抗性疾患の治療に使用するための薬学的組成物。
- 請求項6から10の何れか一項に記載のIL−17Aおよび/またはIL−17Fアンタゴニストを含む、請求項15に記載の薬学的組成物。
- インスリン抵抗性疾患を治療するためのキットであって、(a)IL−17Aおよび/またはIL−17Fアンタゴニストを含む容器と、(b)前記抗体を投与して前記疾患を治療するためのラベルまたは説明書を備える、キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16567709P | 2009-04-01 | 2009-04-01 | |
US61/165,677 | 2009-04-01 | ||
PCT/US2010/029280 WO2010114859A1 (en) | 2009-04-01 | 2010-03-30 | Treatment of insulin-resistant disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012522788A JP2012522788A (ja) | 2012-09-27 |
JP2012522788A5 true JP2012522788A5 (ja) | 2013-05-16 |
JP5795306B2 JP5795306B2 (ja) | 2015-10-14 |
Family
ID=42229822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012503632A Active JP5795306B2 (ja) | 2009-04-01 | 2010-03-30 | インスリン抵抗性疾患の治療 |
Country Status (24)
Country | Link |
---|---|
US (1) | US20100266595A1 (ja) |
EP (1) | EP2413967A1 (ja) |
JP (1) | JP5795306B2 (ja) |
KR (1) | KR101766927B1 (ja) |
CN (1) | CN102448493B (ja) |
AR (1) | AR075998A1 (ja) |
AU (1) | AU2010232692C1 (ja) |
BR (1) | BRPI1011535A2 (ja) |
CA (1) | CA2752908A1 (ja) |
CL (1) | CL2011002416A1 (ja) |
CO (1) | CO6410313A2 (ja) |
CR (1) | CR20110552A (ja) |
EC (1) | ECSP11011429A (ja) |
IL (1) | IL214745A0 (ja) |
MA (1) | MA33248B1 (ja) |
MX (1) | MX347978B (ja) |
NZ (1) | NZ595005A (ja) |
PE (1) | PE20120628A1 (ja) |
RU (1) | RU2537142C2 (ja) |
SG (1) | SG174891A1 (ja) |
TW (1) | TWI474833B (ja) |
UA (1) | UA105384C2 (ja) |
WO (1) | WO2010114859A1 (ja) |
ZA (1) | ZA201106076B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050118232A1 (en) * | 2002-02-12 | 2005-06-02 | Elvira Pistolesi | N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids |
KR20150002874A (ko) | 2008-05-05 | 2015-01-07 | 노비뮨 에스 에이 | 항-il-17a/il-17f 교차-반응성 항체 및 그의 사용 방법 |
US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
EP2633317A1 (en) | 2010-10-25 | 2013-09-04 | Genentech, Inc. | Treatment of gastrointestinal inflammation and psoriasis a |
US9117641B2 (en) | 2012-10-29 | 2015-08-25 | Perkinelmer Health Sciences, Inc. | Direct sample analysis device adapters and methods of using them |
TWI780236B (zh) * | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
PT2950780T (pt) * | 2013-02-04 | 2020-07-07 | Sanofi Sa | Formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina |
CN112957455A (zh) | 2014-01-09 | 2021-06-15 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂 |
US10858427B2 (en) | 2017-03-10 | 2020-12-08 | Suzhou Kanova Biopharmaceutical Co., Ltd. | Monoclonal antibody against both IL-17A and IL-17F and use of the same |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4783469A (en) | 1986-03-07 | 1988-11-08 | Meier Albert H | Method of inhibiting body fat stores |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5266561A (en) | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
WO1990001038A1 (en) | 1988-07-20 | 1990-02-08 | Nordisk Gentofte A/S | Human insulin analogs and preparations containing them |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
ATE295420T1 (de) | 1992-02-06 | 2005-05-15 | Chiron Corp | Marker für krebs und biosynthetisches bindeprotein dafür |
CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
AU682156B2 (en) | 1992-10-15 | 1997-09-25 | Dana-Farber Cancer Institute, Inc. | Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-alpha function |
US5527307A (en) | 1994-04-01 | 1996-06-18 | Minimed Inc. | Implantable medication infusion pump with discharge side port |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US5569186A (en) | 1994-04-25 | 1996-10-29 | Minimed Inc. | Closed loop infusion pump system with removable glucose sensor |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5939269A (en) | 1994-12-28 | 1999-08-17 | The Regents Of The University Of California | Antagonists to insulin receptor tyrosine kinase inhibitor |
US5637095A (en) | 1995-01-13 | 1997-06-10 | Minimed Inc. | Medication infusion pump with flexible drive plunger |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1997004801A1 (en) | 1995-07-27 | 1997-02-13 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
EP0766966A3 (en) | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
IL120443A (en) | 1996-03-18 | 2000-07-16 | Sankyo Co | Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
US20020177188A1 (en) * | 1998-05-15 | 2002-11-28 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US6040292A (en) | 1999-06-04 | 2000-03-21 | Celtrix Pharmaceuticals, Inc. | Methods for treating diabetes |
US6187333B1 (en) | 1999-09-20 | 2001-02-13 | Diabex, Inc. | Method for treating, controlling, and preventing diabetes mellitus |
PT1897944E (pt) | 1999-12-23 | 2011-11-28 | Genentech Inc | Polipéptidos homólogos de il-17 e suas utilizações terapêuticas |
US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
IL161198A0 (en) | 2001-10-15 | 2004-08-31 | Genentech Inc | Treatment and diagnosis of insulin resistant states |
AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
AU2005286474A1 (en) * | 2004-09-21 | 2006-03-30 | Merck Serono Sa | Use of IL-17F for the treatment and/or prevention of neurologic diseases |
ES2333260T3 (es) * | 2005-09-01 | 2010-02-18 | Schering Corporation | Uso de antagonistas de il-23 e il-17 para tratar la enfermedad inflamatoria ocular autoinmunologica. |
US7790163B2 (en) * | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
US7910703B2 (en) * | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
ES2463482T3 (es) * | 2007-04-27 | 2014-05-28 | Zymogenetics, Inc. | Anticuerpos que se unen a IL-17a y a IL-17f y procedimientos de uso de los mismos |
ES2465223T3 (es) * | 2007-04-27 | 2014-06-05 | Zymogenetics, Inc. | Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso |
WO2009015063A2 (en) * | 2007-07-23 | 2009-01-29 | Centocor | Methods and compositions for treating fibrosis related disorders using il-17 antagonists |
CA2701494A1 (en) * | 2007-10-02 | 2009-04-09 | Institut National De La Recherche Scientifique | Method of regulating the th17 pathway and its associated metabolic impact |
-
2010
- 2010-03-30 KR KR1020117025865A patent/KR101766927B1/ko active IP Right Grant
- 2010-03-30 CA CA2752908A patent/CA2752908A1/en not_active Abandoned
- 2010-03-30 MX MX2011010273A patent/MX347978B/es active IP Right Grant
- 2010-03-30 TW TW099109698A patent/TWI474833B/zh not_active IP Right Cessation
- 2010-03-30 UA UAA201112634A patent/UA105384C2/ru unknown
- 2010-03-30 RU RU2011144122/15A patent/RU2537142C2/ru not_active IP Right Cessation
- 2010-03-30 AR ARP100101033A patent/AR075998A1/es not_active Application Discontinuation
- 2010-03-30 AU AU2010232692A patent/AU2010232692C1/en not_active Ceased
- 2010-03-30 NZ NZ595005A patent/NZ595005A/en not_active IP Right Cessation
- 2010-03-30 JP JP2012503632A patent/JP5795306B2/ja active Active
- 2010-03-30 US US12/749,876 patent/US20100266595A1/en not_active Abandoned
- 2010-03-30 WO PCT/US2010/029280 patent/WO2010114859A1/en active Application Filing
- 2010-03-30 CN CN201080023924.3A patent/CN102448493B/zh active Active
- 2010-03-30 PE PE2011001691A patent/PE20120628A1/es not_active Application Discontinuation
- 2010-03-30 EP EP10712243A patent/EP2413967A1/en not_active Withdrawn
- 2010-03-30 MA MA34316A patent/MA33248B1/fr unknown
- 2010-03-30 BR BRPI1011535A patent/BRPI1011535A2/pt not_active IP Right Cessation
- 2010-03-30 SG SG2011068293A patent/SG174891A1/en unknown
-
2011
- 2011-08-18 ZA ZA2011/06076A patent/ZA201106076B/en unknown
- 2011-08-18 IL IL214745A patent/IL214745A0/en unknown
- 2011-08-24 CO CO11108185A patent/CO6410313A2/es not_active Application Discontinuation
- 2011-09-30 CL CL2011002416A patent/CL2011002416A1/es unknown
- 2011-10-19 CR CR20110552A patent/CR20110552A/es unknown
- 2011-11-01 EC EC2011011429A patent/ECSP11011429A/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012522788A5 (ja) | ||
RU2011144122A (ru) | Лечение нарушений, связанных с инсулинорезистентностью | |
JP2009511480A5 (ja) | ||
JP2017048208A5 (ja) | ||
JP2014533279A5 (ja) | ||
JP2017507652A5 (ja) | ||
JP2011507891A5 (ja) | ||
AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
JP2017079785A5 (ja) | ||
JP2009519257A5 (ja) | ||
JP2011184466A5 (ja) | ||
JP2015534578A5 (ja) | ||
JP2011157378A5 (ja) | ||
JP2014534239A5 (ja) | ||
HRP20141194T1 (hr) | Postupci lijeäśenja gihta | |
JP2015534579A5 (ja) | ||
JP2013518912A5 (ja) | ||
JP2012046518A5 (ja) | ||
JP2004536072A5 (ja) | ||
JP2010500360A5 (ja) | ||
JP2013538796A5 (ja) | ||
JP2010505850A5 (ja) | ||
JP2010500370A5 (ja) | ||
JP2016116527A5 (ja) | ||
JP2015530399A5 (ja) |